Therapeutic Asset Ratings

329 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
jy232 Plasma Cell Myeloma	Shenzhen Genocury Biotech Co., Ltd.	Early P1	C (33)
Lvivo-Tavec400 Product Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Early P1	C (33)
nkg2d chimeric antigen receptor nk cell Plasma Cell Myeloma	Changzhou No.2 People's Hospital	Early P1	C (33)
Prochlorperazine Plasma Cell Myeloma	Koen van Besien	Early P1	C (33)
rn1101 Plasma Cell Myeloma	YANRU WANG	Early P1	C (33)
Senl103 Plasma Cell Myeloma	Hebei Senlang Biotechnology Inc., Ltd.	Early P1	C (33)
VITAMIN D Plasma Cell Myeloma	Amany Keruakous, MD, MS.	Early P1	C (33)
Lemzoparlimab Plasma Cell Myeloma	AbbVie	P1	D (31)
Rivogenlecleucel Plasma Cell Myeloma	Bellicum Pharmaceuticals	P1	D (28)
[18f]psma-1007 Plasma Cell Myeloma	First Hospital of China Medical University	N/A	D (26)
Activated T Cells Multiple Myeloma	Massachusetts General Hospital		D (26)
Bcma-Ucart Plasma Cell Myeloma	Bioray Laboratories	N/A	D (26)
Belantamab mafodotin blmf Plasma Cell Myeloma	Duke University		D (26)
Cafizomide Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	N/A	D (26)
ct0594cp Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	N/A	D (26)
Florbetaben Plasma Cell Myeloma	University of Zurich	N/A	D (26)
Gadobutrol Multiple Myeloma	University Hospital, Bonn		D (26)
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE 1 (EC:3.2.2.6) (ADPRC 1/CADRP HYDROLASE 1, CELL SURFACE ANTIGEN CD38)), HUMANIZED MONOCLONAL ANTIBODY, FUSED AT EACH C-TERMINUS OF THE HEAVY CHAINS (1-447, 1''-447'') TO ATTENUATED HUMAN INTERFERON .ALPHA.-2B (IFN.ALPHA.2B) VARIANT (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); GAMMA4 HEAVY CHAIN HUMANIZED FUSED TO IFN.ALPHA.2B (1-612) (VH (HOMO SAPIENS IGHV1-69-201 (90.7%)-(IGHD)-IGHJ401 (85.7%)) CDRIMGT (8.8.13) (26-33.51-58.97-109) (1-120)-HOMO SAPIENS IGHG401, G4V5 H P10 (CH1 (121-218), HINGE 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), FUSED TO IFN.ALPHA.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-3301 (83.2%)-IGKJ401 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (226-226'':229-229'')-BISDISULFIDE; PRODUCED IN CHINESE HAMSTER OVARY (CHO) K1SV CELLS, GLYCOFORM ALFA Plasma Cell Myeloma	Teva Branded Pharmaceutical Products R&D LLC	P1/2	D (26)
Jcar017 (Lisocabtagene Maraleucel) Plasma Cell Myeloma	Bristol-Myers Squibb		D (26)
NORMAL HUMAN SERUM ALBUMIN Plasma Cell Myeloma	Assiut University		D (26)
pd1-bcma-cart Plasma Cell Myeloma	Bioray Laboratories	N/A	D (26)
Peg-Rhg-Csf Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	N/A	D (26)
Sulpegfilgrastim Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	N/A	D (26)
Zn-Ddc Plasma Cell Myeloma	The Royal Wolverhampton Hospitals NHS Trust		D (26)
gi-4000 Multiple Myeloma	Massachusetts General Hospital		D (25)

Showing 301 to 325 of 329 assets

PreviousPage 13 of 14Next